WO2001047549A3 - Conjugate useful as building block for vaccine preparation - Google Patents
Conjugate useful as building block for vaccine preparation Download PDFInfo
- Publication number
- WO2001047549A3 WO2001047549A3 PCT/GB2000/004951 GB0004951W WO0147549A3 WO 2001047549 A3 WO2001047549 A3 WO 2001047549A3 GB 0004951 W GB0004951 W GB 0004951W WO 0147549 A3 WO0147549 A3 WO 0147549A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- building block
- vaccine preparation
- conjugate useful
- conjugate
- useful
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6018—Lipids, e.g. in lipopeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
A polymerisable compound for use as a medicament, comprising a peptide; a spacer covalently linked to the peptide; and a monomer unit covalently linked to the spacer and capable of forming a polymer with at least one further monomer unit in a further polymerisable compound.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9930585A GB9930585D0 (en) | 1999-12-23 | 1999-12-23 | Component for vaccine |
| GB9930585.6 | 1999-12-23 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2001047549A2 WO2001047549A2 (en) | 2001-07-05 |
| WO2001047549A3 true WO2001047549A3 (en) | 2001-12-27 |
Family
ID=10866996
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/GB2000/004951 Ceased WO2001047549A2 (en) | 1999-12-23 | 2000-12-21 | Conjugate useful as building block for vaccine preparation |
Country Status (2)
| Country | Link |
|---|---|
| GB (1) | GB9930585D0 (en) |
| WO (1) | WO2001047549A2 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103275178B (en) * | 2013-05-21 | 2015-04-29 | 首都医科大学 | Preparation of n-dodecanoic acid-RGD (arginine-glycine-aspartic acid)-n-tetradecanol mediated fanny targeted liposome, and evaluation of anti-tumor activity |
| EP3773483A4 (en) * | 2018-04-06 | 2022-01-26 | Amma Therapeutics, Inc. | CONTROLLED RELEASE THERAPEUTIC COMPOSITION |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998034968A1 (en) * | 1997-02-11 | 1998-08-13 | The Council Of The Queensland Institute Of Medical Research | Polymers incorporating peptides |
-
1999
- 1999-12-23 GB GB9930585A patent/GB9930585D0/en not_active Ceased
-
2000
- 2000-12-21 WO PCT/GB2000/004951 patent/WO2001047549A2/en not_active Ceased
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998034968A1 (en) * | 1997-02-11 | 1998-08-13 | The Council Of The Queensland Institute Of Medical Research | Polymers incorporating peptides |
Non-Patent Citations (4)
| Title |
|---|
| CHEMICAL ABSTRACTS, vol. 101, no. 21, 19 November 1984, Columbus, Ohio, US; abstract no. 189405, PETROV, R. V. ET AL: "Vaccinating effect of conjugates of influenza virus surface antigens with synthetic polymer carrier" XP002167382 * |
| D C JACKSON ET AL.: "Free radical induced polymerization of synthetic peptides into polymeric immunogens", VACCINE., vol. 15, no. 15, 1997, BUTTERWORTH SCIENTIFIC. GUILDFORD., GB, pages 1697 - 1705, XP002167381, ISSN: 0264-410X * |
| DOKL. AKAD. NAUK SSSR (1984), 277(3), 752-5 [IMMUNOL.], 1984 * |
| N M O'BRIEN-SIMPSON ET AL.: "Polymerization of unprotected synthetic peptides: a view toward synthetic peptide vaccines", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY., vol. 119, no. 6, 1997, AMERICAN CHEMICAL SOCIETY, WASHINGTON, DC., US, pages 1183 - 1188, XP002167380, ISSN: 0002-7863 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2001047549A2 (en) | 2001-07-05 |
| GB9930585D0 (en) | 2000-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU3177700A (en) | Polymers, their preparation and uses | |
| PT1572728E (en) | Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof | |
| WO2000041538A3 (en) | Dermal compositions | |
| AU2001241423A1 (en) | Needleless syringe | |
| CA2332559A1 (en) | High molecular weight medicine-containing preparation in powder form for administration through mucosa | |
| AU2002225762A1 (en) | Preparation of polymerization catalysts | |
| AU3958100A (en) | New compounds, their preparation and use | |
| AU3958200A (en) | New compounds, their preparation and use | |
| WO2003000226A3 (en) | Pharmaceutical compositions containing polymer and drug assemblies | |
| AU2002233986A1 (en) | Rigid soluble materials for use with needle-less infusion sets, sensor sets and injection devices and methods of making the same | |
| AU2003289641A1 (en) | The novel coumarin-amide derivatives and its preparation, said drug composition and its use | |
| WO2003086369A3 (en) | Stealthy polymeric biodegradable nanospheres and uses thereof | |
| AU2001282267A1 (en) | Benzimidazole derivatives, preparation and therapeutic use thereof | |
| AU6303800A (en) | Improvements in or relating to polymers | |
| AU2002213181A1 (en) | Nanostructures formed through cyclohexadiene polymerization | |
| AU2922600A (en) | Pyridopyranoazepine derivatives, preparation and therapeutic use | |
| AU2001235773A1 (en) | Electro-luminiscent polymers, their preparation and uses | |
| AU2001277605A1 (en) | High molecular weight cationic polymers, preparation method and uses thereof | |
| WO2004029073A3 (en) | Conjugates comprised of polymer and hiv gp41-derived peptides and their use in therapy | |
| WO2001047549A3 (en) | Conjugate useful as building block for vaccine preparation | |
| AU2001260110A1 (en) | Novel LHRH-antagonists, Production and Use Thereof as Medicament | |
| ZA200110244B (en) | Novel xanthone compounds, their preparation and use as medicament. | |
| AUPR218000A0 (en) | Polymer gels and their preparation | |
| AU2001268653A1 (en) | Combination hiv therapy including camptothecin | |
| AU6846500A (en) | Novel 8-carbonyl chroman derivatives, preparation and therapeutic use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): JP US |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| AK | Designated states |
Kind code of ref document: A3 Designated state(s): JP US |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR |
|
| 122 | Ep: pct application non-entry in european phase | ||
| NENP | Non-entry into the national phase |
Ref country code: JP |